Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 449 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CIS Clear all
Terminated Phase 1 Interventional

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05014139
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Interventions
Enfortumab vedotin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer

NCT00749437
View directory record Official record
Conditions
Breast Cancer
Interventions
3-dimensional conformal accelerated partial breast irradiation
Radiation
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
45 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 31, 2026, 1:43 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

NCT02336984
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2 pulsed DC1, trastuzumab, pertuzumab
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 31, 2026, 1:43 PM EDT
Not listed Not applicable Interventional

Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia

NCT02406352
View directory record Official record
Conditions
Carcinoma in Situ of Uterine Cervix, Cervical Intraepithelial Neoplasias, High Grade Cervical Intraepithelial Neoplasia
Interventions
Multispectral Digital Colposcope with probe
Device
Lead sponsor
Brookdale University Hospital Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 31, 2026, 1:43 PM EDT
Recruiting Phase 3 Interventional

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

NCT01185132
View directory record Official record
Conditions
Breast Cancer
Interventions
accelerated partial breast irradiation - 3D-conformal planning, accelerated partial breast irradiation - IMRT planning
Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
40 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Boulder, Colorado • Lakewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 31, 2026, 1:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Increasing PrEP Awareness and Demand Among Black Cisgender Women

NCT05896423
View directory record Official record
Conditions
HIV, PrEP
Interventions
PrEP awareness materials
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Months to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 31, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

NCT00290654
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen, Lumpectomy, brachytherapy
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 31, 2026, 1:43 PM EDT
Completed No phase listed Observational

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

NCT00719966
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, exemestane, letrozole, assessment of therapy complications
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 31, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional

Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ

NCT00002934
View directory record Official record
Conditions
Breast Cancer
Interventions
long-term screening
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
29
States / cities
Atlanta, Georgia • Decatur, Georgia • Evanston, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

NCT00334789
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Belinostat, Isotretinoin, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Lycopene on High Risk Prostatic Tissue

NCT01443026
View directory record Official record
Conditions
Intraepithelial Prostatic Neoplasia, Prostatic Neoplasms
Interventions
Lycopene 30mg, Placebo
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
40 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
La Jolla, California • Orange, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors

NCT03039140
View directory record Official record
Conditions
Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Educational Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 31, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors

NCT07699991
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Localized Breast Carcinoma
Interventions
Best Practice, Patient Navigation, Referral, Survey Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

NCT00106691
View directory record Official record
Conditions
Preneoplastic Conditions, Prostatic Intraepithelial Neoplasia
Interventions
Toremifene 20 mg, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older · Male only
Enrollment
1,589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
108
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 31, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Atacicept in Subjects With Optic Neuritis

NCT00624468
View directory record Official record
Conditions
Optic Neuritis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 31, 2026, 1:43 PM EDT
Active, not recruiting Not applicable Interventional

Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study

NCT04754412
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Behavioral, Psychological or Informational Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence

NCT04054557
View directory record Official record
Conditions
Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage III Breast Cancer AJCC v7
Interventions
Telemedicine, Best Practice, Questionnaire Administration, Quality-of-Life Assessment, Survey Administration, Behavioral Intervention, Educational Intervention
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Washington Township, New Jersey • Philadelphia, Pennsylvania • Torresdale, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

NCT07095114
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Magic Ink
Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 31, 2026, 1:43 PM EDT
Active, not recruiting Phase 2 Interventional

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast

NCT04009044
View directory record Official record
Conditions
Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Afimoxifene, Core Biopsy, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

NCT01869764
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

RA-2 13-cis Retinoic Acid (Isotretinoin)

NCT02061384
View directory record Official record
Conditions
Male Infertility, Klinefelter's Syndrome, Y-chromosome Microdeletions
Interventions
13-cis retinoic acid, Calcitriol
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 60 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 31, 2026, 1:43 PM EDT
Terminated Phase 1 Interventional

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

NCT04185311
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Ipilimumab, Nivolumab, Talimogene Laherparepvec
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 31, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

NCT01293032
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy
Procedure · Other · Genetic + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 31, 2026, 1:43 PM EDT